Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.

Literature DB >> 26028676

Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.

Ye-Rin Lee¹, Min-Hee Kang¹, Hee-Myung Park¹.

Abstract

An 8-year-old American cocker spaniel dog was diagnosed with dilated cardiomyopathy. Four years earlier, the dog had been diagnosed with multicentric lymphoma and had received 4 cycles of multi-agent chemotherapy, including doxorubicin and epirubicin. The total cumulative dose of epirubicin was 168 mg/m(2). Dilated cardiomyopathy was considered a consequence of epirubicin toxicity.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 26028676 PMCID： PMC4431152

Source DB: PubMed Journal: Can Vet J ISSN： 0008-5286 Impact factor: 1.008

30 in total

1. Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline.

Authors: D Skudicky; K Sliwa; A Bergemann; G Candy; P Sareli
Journal: Heart Date: 2000-10 Impact factor: 5.994

2. A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma.

Authors: E Teske; G R Rutteman; J Kirpenstein; J Hirschberger
Journal: Vet Comp Oncol Date: 2011-04-18 Impact factor: 2.613

3. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.

Authors: Lyndsay Harris; Gerald Batist; Robert Belt; Douglas Rovira; Rudolph Navari; Nozar Azarnia; Lauri Welles; Eric Winer
Journal: Cancer Date: 2002-01-01 Impact factor: 6.860

4. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.

Authors: J W Elliott; P Cripps; A M Marrington; I A Grant; L Blackwood
Journal: Vet Comp Oncol Date: 2012-02-28 Impact factor: 2.613

5. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

Authors: G Batist; G Ramakrishnan; C S Rao; A Chandrasekharan; J Gutheil; T Guthrie; P Shah; A Khojasteh; M K Nair; K Hoelzer; K Tkaczuk; Y C Park; L W Lee
Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544

Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.

1. Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline.

2. A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma.

3. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.

4. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.

5. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

6. Uterine carcinoma in a 10-month-old golden retriever.

7. Toxicity associated with epirubicin treatments in a large case series of dogs.

8. Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.

9. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

Review 10. Lymphoma: which chemotherapy protocol and why?

1. Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs.